

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 15, 2003, 00:14:43 ; Search time 373.587 Seconds
(without alignments)
10012.591 Million cell updates/sec

Title: US-09-001-737-7

Perfect score: 1661

Sequence: 1 GAATTCGGCTTCATATGCA.....TGGCGGATAGCCGAATTC 1661

Scoring table:

IDENTITY-NUC
Gapop 10.0, Gapext 1.0

Searched: 2185239 segs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

N_Geneseq_101002:*

1: /SID2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID2/gcgdata/geneseq/geneseq-emb1/NA2001.DAT.*
23: /SID2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*
24: /SID2/gcgdata/geneseq/geneseq-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1661	100.0	1661	20	AAH6155
2	1632.2	97.7	1635	24	ABN69100
3	1413.4	85.1	1683	22	ABN68861
4	1140.4	68.7	1306	22	AAH56862
5	1122.6	67.6	1305	22	AAH56865
6	1063.4	64.0	2155561	24	ABN71527
7	1062.4	64.0	1620	24	ABN69159
8	1052	63.3	1654	20	AAH6153
9	1039.2	62.6	1623	22	AAH90800

10	1038.4	62.5	1926	22	AAH25036
11	1037	62.4	2107	22	AAH56860
12	1036	62.4	1647	22	AAH90806
13	1035.4	62.3	5365	19	AAH52210
14	1030.6	62.0	2401	22	AAH56859
15	955	57.5	2365589	24	ABA90521
16	942.6	56.7	3625	20	AAH12979
17	832	50.1	1901	24	ABO70705
18	824	49.6	213251	24	ABO67193
19	786.4	47.3	1957	22	AAH56867
20	773	46.5	1958	22	AAH56868
21	760.6	45.8	1570	24	ABO69121
22	756.4	45.5	3885	22	AAH54519
23	755.4	45.5	1620	22	AAH52898
24	735.6	44.3	1623	24	ABN92405
25	722.4	43.5	2712	22	AAH56866
26	704.2	42.4	1647	18	AAH69201
27	704.2	42.4	4972	18	AAH69203
28	654.2	39.4	96109	22	AAH28348
29	613.8	37.1	640681	24	ABA92787
30	608.2	36.6	613	22	AAH56864
31	604.2	36.4	609	22	AAH56863
32	590.6	35.6	1665	20	AAH86152
33	589.8	35.5	1647	21	AAH48498
34	589.8	35.5	1647	22	AAH90805
35	589.8	35.5	1647	24	ABH6324
36	589.8	35.5	1741	22	AAH56858
37	589.8	35.5	2155	24	AAH33423
38	589.8	35.5	4524	21	AAH48500
39	583.4	35.1	2032	22	AAH56856
40	577.2	34.8	2006	22	AAH56857
41	568.2	34.2	1662	20	AAH86154
42	552.8	33.3	1635	21	AAH54509
43	551.6	33.2	910715	20	AAH20248
44	550	33.1	2465	12	AAH13136
45	536.8	32.3	1635	21	AAH13000

ALIGNMENTS

RESULT 1	AAH6155	AAH6155 standard; DNA; 1661 BP.
ID	AAH6155;	
AC	AAH6155;	
XX		
DT	22-SEP-1999 (first entry)	
DE	DNA encoding a Streptococcus pyogenes heat shock protein (Hsp)60-2.	
XX		
KW	Heat shock protein; Hsp60-2; Immune response; Immunological carrier; cancer control; tumour; sarcoma; cancer; gene therapy; ss.	
OS	Streptococcus pyogenes.	
XX		
PN	W0935270-A1.	
XX		
PD	15-JUL-1999.	
XX		
PE	29-DEC-1998; 98MO-CA01203.	
XX		
FR	31-DEC-1997; 97US-0001737.	
XX		
PA	(STRE-) STRESSGEN BIOTECHNOLOGIES CORP.	
XX		
PI	Mizzen L, Walslewski J;	
XX		
DR	WPI; 1999-430397/36.	
XX	P-PSDB; AAH23904.	
XX	New nucleic acid encoding heat shock protein-60 from Streptococcus;	
PT	useful in vaccines, as carriers for other immunogens, as anticancer	

PT agents and for diagnosis

PS Claim 3: Fig 4A-B; 176bp; English.

XX The present sequence encodes a heat shock protein, designated Hsp60-2.
 CC The protein, its fragments, variants and fusion proteins, are
 CC used to elicit or enhance an immune response against Streptococcus,
 CC and to elicit a similar response to a target antigen fused to the
 CC protein. Unlike other immunological carriers, Hsp60 proteins are not
 CC immunosuppressive so provide an increased response to any conjugated or
 CC fused antigen. Also, where used for cancer control, they lack the side
 CC effects associated with endotoxins. They can also be used to detect
 CC specific antibodies and in treatment or prevention of tumours
 CC (e.g. sarcoma or cancers of breast, ovary, prostate, lung, pancreas or
 CC liver). The Hsp60 polynucleotide is used for recombinant production
 CC of the protein, as a source of primers and probes for detecting
 CC streptococci in standard hybridization/amplification assay, and
 CC therapeutically in gene therapy vectors.

SQ Sequence 1661 BP; 512 A; 308 C; 407 G; 434 T; 0 other:

Query Match 100.0%; Score 1661; DB 20; Length 1661;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1661; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

0Y 1 GAATTCGGCTTCATATGCGAAGAAAGAAATTCGACGATGCGGCTGCTCCATG 60
 DB 1 GAATTCGGCTTCATATGCGAAGAAAGAAATTCGACGATGCGGCTGCTCCATG 60
 0Y 61 TCGCGGAGTTGATATGTTAGACATACGCTCAAGTACGCTTGTCTTAAAGGCGCA 120
 DB 61 TCGCGGAGTTGATATGTTAGACATACGCTCAAGTACGCTTGTCTTAAAGGCGCA 120
 0Y 121 ATGCTGTTCTTGAAGAAAGCTTTGGTCTCCCTTAATTAATGACGGGGTAAACATTG 180
 DB 121 ATGCTGTTCTTGAAGAAAGCTTTGGTCTCCCTTAATTAATGACGGGGTAAACATTG 180
 0Y 181 CTAAGAGATGATAGATAGATGATTTGAAAGATGAGGCAAAATTTGGTGTCAAG 240
 DB 181 CTAAGAGATGATAGATAGATGATTTGAAAGATGAGGCAAAATTTGGTGTCAAG 240
 0Y 241 TGGCTCTTAAGCAATGATATGCTGTGATGAGGACACACTGCAACAGTTTGAC 300
 DB 241 TGGCTCTTAAGCAATGATATGCTGTGATGAGGACACACTGCAACAGTTTGAC 300
 0Y 301 AAGCCATTTGTCATGAAAGAGCTAAAGAAATGACAGAGCTGTAATTCATTTGCTTC 360
 DB 301 AAGCCATTTGTCATGAAAGAGCTAAAGAAATGACAGAGCTGTAATTCATTTGCTTC 360
 0Y 361 GTGAGGCAATGAAACAGACAGACAGCTGTTGAAGCCTTGAAGCATTGCTCAAC 420
 DB 361 GTGAGGCAATGAAACAGACAGACAGCTGTTGAAGCCTTGAAGCATTGCTCAAC 420
 0Y 421 CTGTATCTGGCAGAGAGCTATGCTAGCTGCTGACATATCAGCTCTGTAAG 480
 DB 421 CTGTATCTGGCAGAGAGCTATGCTAGCTGCTGACATATCAGCTCTGTAAG 480
 0Y 481 TTGAGAGATATATCTGAGAGCTATGAGAGCTGTGGGACAGATGATGATACATG 540
 DB 481 TTGAGAGATATATCTGAGAGCTATGAGAGCTGTGGGACAGATGATGATACATG 540
 0Y 541 AAGAAATCTCGAGATGAGAAAGAACTGAGAGCTGTTGAAGGCAATTTACCGTG 600
 DB 541 AAGAAATCTCGAGATGAGAAAGAACTGAGAGCTGTTGAAGGCAATTTACCGTG 600
 0Y 601 GTTACCTGCTCAATACATGTCACACACATGAAATGTTGTCAGACCTTGAAGCC 660
 DB 601 GTTACCTGCTCAATACATGTCACACACATGAAATGTTGTCAGACCTTGAAGCC 660
 0Y 661 CATTTATTTATACGAGATGAAAGAGTCAACATTCACAGATTTTGCACACTACTG 720
 DB 661 CATTTATTTATACGAGATGAAAGAGTCAACATTCACAGATTTTGCACACTACTG 720

0Y 721 AGCAATGTTCTTAAGAACACACCGCTCATTTACTATTTGCAAGATGATGATGATGAG 780
 DB 721 AGCAATGTTCTTAAGAACACACCGCTCATTTACTATTTGCAAGATGATGATGATGAG 780
 0Y 781 CACTTCCAAACCTTGTCTTGAACAGATTCGTGACTTTCATATGTTGCTGTCAAG 840
 DB 781 CACTTCCAAACCTTGTCTTGAACAGATTCGTGACTTTCATATGTTGCTGTCAAG 840
 0Y 841 CGCCAGATTTGTGATGCTGTGAAGATGATGATGATGATGATGATGATGATGATGAT 900
 DB 841 CGCCAGATTTGTGATGCTGTGAAGATGATGATGATGATGATGATGATGATGATGAT 900
 0Y 901 GTACAGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 960
 DB 901 GTACAGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 960
 0Y 961 GACAGGCTGCTAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1020
 DB 961 GACAGGCTGCTAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1020
 0Y 1021 GTTACAGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1080
 DB 1021 GTTACAGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1080
 0Y 1081 CTGACTTTGACCGTGAAGAACTGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
 DB 1081 CTGACTTTGACCGTGAAGAACTGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
 0Y 1141 TTATCAAGATGAG 1200
 DB 1141 TTATCAAGATGAG 1200
 0Y 1201 ATGCTCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1260
 DB 1201 ATGCTCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1260
 0Y 1261 CACTTATTCAGGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1320
 DB 1261 CACTTATTCAGGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1320
 0Y 1321 GAGTATACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380
 DB 1321 GAGTATACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380
 0Y 1381 GGTACAGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440
 DB 1381 GGTACAGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440
 0Y 1441 ATGCTCAAG 1500
 DB 1441 ATGCTCAAG 1500
 0Y 1501 TAACAGATGAG 1560
 DB 1501 TAACAGATGAG 1560
 0Y 1561 CAGTGTGCTATTAATCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1620
 DB 1561 CAGTGTGCTATTAATCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1620
 0Y 1621 ATCCAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1680
 DB 1621 ATCCAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1680

RESULT 2

ABN69160 ID ABN69160 standard; DNA: 1635 BP.

XX ABN69160:

DT 01-JUL-2002 (first entry)

DE Streptococcus polynucleotide SEQ ID NO 6233.
XX
KW Streptococcus: GAS, GBS, group B streptococcus; Streptococcus agalactiae;
KW group A streptococcus; Streptococcus pyogenes; antibacterial; gene;
KW antiinflammatory; infection; vaccine; meningitis; gene therapy; ds.
OS Streptococcus pyogenes.
XX
FN MO200234771-A2.
XX
PD 02-MAY-2002.
XX
PF 29-OCT-2001; 2001MO-GB04789.
XX
PR 27-OCT-2000; 2000GB-0026333.
PR 24-NOV-2000; 2000GB-0028727.
PR 07-MAR-2001; 2001GB-0005640.
XX
PA (CHIR-) CHIRON SPA.
XX (GENO-) INST GENOMIC RES.
PI Telford J, Maignanl V, Margalit Ros YI, Grandl G, Fraser C;
PI Tellelin H;
XX WPI: 2002-352536/38.
DR P-PSDB; ABP28529.
XX
PT New Streptococcus protein for the treatment or prevention of infection
or disease caused by Streptococcus bacteria, such as meningitis, and
for detecting a compound that binds to the protein -
XX
PS Claim 7; Page 3785-3786; 4525pp; English.
XX
XX The invention relates to a protein (ABP25413-ABP30895) from group B
streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
(Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
the specification. The proteins have antibacterial and antiinflammatory
activity. (I), nucleic acids encoding (II), ABN6044-ABN7156 and
antibodies that bind (I) are used in the manufacture of medicaments for
the treatment or prevention of infection or disease caused by
Streptococcus bacteria, particularly S. agalactiae and S. pyogenes.
CC Nucleic acids encoding (I) are used to detect Streptococcus in a
biological sample. (I) is used to determine whether a compound binds to
CC (II). A composition comprising (I) or a nucleic acid encoding (I), may be
used as a vaccine or diagnostic composition. The disease caused by
Streptococcus that is prevented or treated may be meningitis. Nucleic
acid encoding (I) may be used to recombinantly produce (I) and may be
used in gene therapy. Antibodies to (I) are used for affinity
chromatography, immunoassays, and distinguishing/identifying
Streptococcus proteins.
XX
XX
SO Sequence 1635 BP; 504 A; 303 C; 397 G; 431 T; 0 other;
Query Match 97.7%; Score 1622.2; DB 24; Length 1635;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1624; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 253 CCAATGATATTCGCTGATGGAGAGACTACTGCAACAGTTTGTGACACAGCATTTGCTC 312
DB CCATGATATTCGCTGATGGAGAGACTACTGCAACAGTTTGTGACACAGCATTTGCTC 304
QY 313 ATGAGAGACTAATAAATGATGACAGCAGGTGCTATTCATTTGATGATCCGTCAGGCAATG 372
DB ATGAGAGACTAATAAATGATGACAGCAGGTGCTATTCATTTGATGATCCGTCAGGCAATG 364
QY 373 AAGACGACAGCAACAGCTGTTGAAGCTTGAAGCCATTTGCTCAACCTGATATGCGCA 432
DB AAGACGACAGCAACAGCTGTTGAAGCTTGAAGCCATTTGCTCAACCTGATATGCGCA 424
QY 433 AGGAGCTATTTGCTCAGGTGCTGCTGATATCAGCTCTGAAAAAGTTGAGAGATGA 492
DB AGGAGCTATTTGCTCAGGTGCTGCTGATATCAGCTCTGAAAAAGTTGAGAGATGA 484
QY 493 TCTCAGAACCTATGAGCCGTGTGGCAACAGATGCTGATTTACCATCGAAGATCTGAG 552
DB TCTCAGAACCTATGAGCCGTGTGGCAACAGATGCTGATTTACCATCGAAGATCTGAG 544
QY 553 GTATGGAACAGAACTTGAAGTGTGGAAGCATATTTGACCGGTGTTACGTCCTC 612
DB GTATGGAACAGAACTTGAAGTGTGGAAGCATATTTGACCGGTGTTACGTCCTC 604
QY 613 AATACATGCTCAGACATGAAATAATGGTTGACAGCTTGAATAACCATTTATCTTAA 672
DB AATACATGCTCAGACATGAAATAATGGTTGACAGCTTGAATAACCATTTATCTTAA 664
QY 673 TCACGATTAATAAAGTGTCAAAATCCAGACATTTTGCCTACTTGTGAGAAAGTTCTTA 732
DB TCACGATTAATAAAGTGTCAAAATCCAGACATTTTGCCTACTTGTGAGAAAGTTCTTA 724
QY 733 AAACCAACCCGCTCTTACATTTATGCAATGATGATGATGTAAGCATTTCCACCC 792
DB AAACCAACCCGCTCTTACATTTATGCAATGATGATGATGTAAGCATTTCCACCC 784
QY 793 TTCTCTGACACAGATTCGTGTGATCTTCAATGATGATGATGATGATGATGATGATG 852
DB TTCTCTGACACAGATTCGTGTGATCTTCAATGATGATGATGATGATGATGATGATG 844
QY 853 GTGATGCTGCTGAAGATGCTTGAAGACATTTGCTATCTTGAAGAGTGTGATGATTA 912
DB GTGATGCTGCTGAAGATGCTTGAAGACATTTGCTATCTTGAAGAGTGTGATGATTA 904
QY 913 CAGAGATCTAGCATTTGAATTAATAAGATGCTCAATGACAGCCCTTGACAGGCTGCTTA 972
DB CAGAGATCTAGCATTTGAATTAATAAGATGCTCAATGACAGCCCTTGACAGGCTGCTTA 964
QY 973 AGATTACGATGATTAAGATGACAGTAAATGTTGAAGAGTGTGAGAGATGACAGATTA 1032
DB AGATTACGATGATTAAGATGACAGTAAATGTTGAAGAGTGTGAGAGATGACAGATTA 1024
QY 1033 TTGCTAACCGATTTGCTACATGATTAATTCGATTTGAACACAGCTTCTGACTTGAAC 1092
DB TTGCTAACCGATTTGCTACATGATTAATTCGATTTGAACACAGCTTCTGACTTGAAC 1084
QY 1093 GTGAAAACTTCAAGAAAGCTTTGGCGAAATTAAGTGTGATGATGATGATGATGATG 1152
DB GTGAAAACTTCAAGAAAGCTTTGGCGAAATTAAGTGTGATGATGATGATGATGATG 1144
QY 1153 GAGCTCCAGAGAGAGAGCTTTAAAGAAATTAATTCGATTTGAGATGCTCTAAAG 1212
DB GAGCTCCAGAGAGAGAGCTTTAAAGAAATTAATTCGATTTGAGATGCTCTCTAAAG 1204
QY 1213 CTACAGCGTGAAGCGTTGAAGAGTATGCTGTGAGTGAAGAGAGAGAGAGAGAGAG 1272
DB CTACAGCGTGAAGCGTTGAAGAGTATGCTGTGAGTGAAGAGAGAGAGAGAGAGAG 1264
QY 1273 TTATGAAAAAGTGAAGAGCTTGTAGCTTGAAGAGAGAGAGAGAGAGAGAGAGAGAG 1332
DB TTATGAAAAAGTGAAGAGCTTGTAGCTTGAAGAGAGAGAGAGAGAGAGAGAGAGAG 1324
QY 1333 TGCTTGTGCTCTAGAAAGCCCTGTACGTCAAATTTGCTTAAATGCTGGTACGAAGCT 1392

Db 1325 TCGTCTGCTCTAGAGACCCCTGACGTCAGTAAATGCTGAGGCTGAGAGGCT 1384
 OY 1393 CCGAGCTTTTTCACAGTTTAAACACCCCTGACGAGACGATTTATGCTGCACAG 1452
 Db 1385 CCGAGCTTTTTCACAGTTTAAACACCCCTGACGAGACGATTTATGCTGCACAG 1444
 OY 1453 GTGAGTGGTGTATATATTAACAGGATCATTTACCTGTCGTAAGTACAGCATCAG 1512
 Db 1445 GTGAGTGGTGTATATATTAACAGGATCATTTACCTGTCGTAAGTACAGCATCAG 1504
 OY 1513 CGCTTCAAAATGACAGCTTCTGTAGTACTCTTATTTGACAAAGAGAGCTGTTGCTA 1572
 Db 1505 CGCTTCAAAATGACAGCTTCTGTAGTACTCTTATTTGACAAAGAGAGCTGTTGCTA 1564
 OY 1573 ATAACTCAACAGCTACGCGGACGAGCATGCGACAGGATGATGAGGATGA 1632
 Db 1565 ATAACTCAACAGCTACGCGGACGAGCATGCGACAGGATGATGAGGATGA 1624
 OY 1633 TGGGTGG 1639
 Db 1625 TGGGCGG 1631
 RESULT 3
 AAH56861
 ID AAH56861 standard; DNA: 2683 BP.
 XX
 AC AAH56861:
 XX
 DT 06-SEP-2001 (first entry)
 XX
 DE S. Pyogenes groEL gene partial sequence SEQ ID NO:7.
 XX
 KW Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
 KW microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
 KW Streptococcus pyogenes; Streptococcus aureus; Pseudomonas aeruginosa;
 KW antibacterial; antiviral; antiproliferative; antisense therapy;
 KW microbial infection; ds.
 XX
 OS Streptococcus pyogenes.
 XX
 PN WO200136625-A2.
 XX
 PD 25-MAY-2001.
 XX
 PF 20-NOV-2000; 2000WO-CN01347.
 XX
 PR 18-NOV-1999; 99US-0166249.
 XX
 PA (GENE-) GENESENSE TECHNOLOGIES INC.
 XX
 PI Wright JA, Young AH, Dugourd D;
 XX
 DR WPI; 2001-355633/37.
 XX
 PT Novel antisense compounds targeting nucleic acid encoding groEL or
 PT groES gene of microorganism, which hybridize with and inhibit
 PT expression of the genes, useful to inhibit growth of microorganism
 PT having the genes.
 XX
 PS Disclosure: Fig 7; 110pp: English.
 XX
 CC The present invention specifically claims AAH56368 to AAH56832 which are
 CC antisense oligonucleotides to nucleotide sequences encoding groE. More
 CC generally, antisense compounds (I) comprising antisense oligonucleotides
 CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
 CC shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
 CC microorganism, where the antisense compound is complementary to GL or
 CC GS of a microorganism and specifically hybridizes with and inhibits the
 CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral
 CC and antiproliferative activities, and can be used in antisense therapy
 CC and for inhibition of expression of groES or groEL. (I) are useful for

CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
 CC also useful for inhibiting the growth of a microorganism, or inhibiting
 CC the expression of GL or GS gene in a microorganism (a bacterial cell or
 CC a virus) having a GL or GS gene which involves administering to the
 CC microorganism or to a cell infected with the microorganism, (I). (I) are
 CC also useful for treating a mammalian pathological condition mediated by
 CC the microorganisms which involves identifying a eukaryotic organism
 CC having a pathological condition mediated by microorganisms having a GL
 CC or GS gene and administering (I) such that the growth of microorganism
 CC is inhibited. The antisense compounds are utilized for diagnostics,
 CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
 CC prevent or delay microbial infections in humans. They are also useful as
 CC molecular weight markers. AAH56362 to AAH56367 and AAH56832 to AAH56854
 CC represent PCR primers for groE sequences which are used in the
 CC exemplification of the present invention. AAH56855 to AAH56870 represent
 CC groE nucleotide sequence given in the present invention.
 XX
 XX Sequence 2683 BP; 808 A; 490 C; 593 G; 792 T; 0 other;
 Query Match 85.1%; Score 1413.4; DB 22; Length 2683;
 Best Local Similarity 98.9%; Pred. No. 0;
 Matches 1423; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 OY 201 GATCATTTTGAACATGGAGCAAAATGGTCTGAGTGGCTTCAAAACCATGAT 260
 Db 1 GATCATTTGAAACATGGAGCAAAATGGTCTGAGTGGCTTCAAAACCATGAT 60
 OY 261 ATTGCTGCTGATGGAGCACTACTGCAACAGTTTGCACACAGCATTTGTCATAGAGA 320
 Db 61 ATTGCTGCTGATGGAGCACTACTGCAACAGTTTGCACACAGCATTTGTCATAGAGA 120
 OY 321 CTAAAAATGTGACAGCAGTGTCTAATCCAAATGTTATCCGTGAGCATTTGAACAGCA 380
 Db 121 CTAAAAATGTGACAGCAGTGTCTAATCCAAATGTTATCCGTGAGCATTTGAACAGCA 180
 OY 381 ACAGCAACAGCTGTGGAAGCTTGAAGGCAATTCCTCACTGATCTGCAAGAGAGCT 440
 Db 181 ACAGCAACAGCTGTGGAAGCTTGAAGGCAATTCCTCACTGATCTGCAAGAGAGCT 240
 OY 441 ATTCTCAGTGTGCTGAGTATCATACGCTCTGAAAAAGTTGAGAGATATCTCAGAA 500
 Db 241 ATTCTCAGTGTGCTGAGTATCATACGCTCTGAAAAAGTTGAGAGATATCTCAGAA 300
 OY 501 GCTATGAGAGCTGTGGGCAACGATGGTGTGATACATCGAAGATTCGAGGTATGGA 560
 Db 301 GCTATGAGAGCTGTGGGCAACGATGGTGTGATACATCGAAGATTCGAGGTATGGA 360
 OY 561 ACAGACTGAGTGTGGAAGCATGCAATTTGACCGTGTACCTGCTCAATACATG 620
 Db 361 ACAGACTGAGTGTGGAAGCATGCAATTTGACCGTGTACCTGCTCAATACATG 420
 OY 621 GTCACAGACAAATGAAAAATGTTGACAGACTTGAACCCATTATCTTATACAGAT 680
 Db 421 GTCACAGACAAATGAAAAATGTTGACAGACTTGAACCCATTATCTTATATGAT 480
 OY 681 AAAAAAGTCAACATCCAGACATTTGGCACTACTGAGAGATCTTAAACCAAC 740
 Db 481 AAAAAAGTCAACATCCAGACATTTGGCACTACTGAGAGATCTTAAACCAAC 540
 OY 741 CGTCCATTACTATTATTCAGATGATGAGTGTGAAGCACTTCCAAACCTTGTG 800
 Db 541 CGTCCATTACTATTATTCAGATGATGAGTGTGAAGCACTTCCAAACCTTGTG 600
 OY 801 AACCAATTCGCTGACTTTCAATGTTCTGTCAAAAGCCCGAGATTTGATGATG 860
 Db 601 AACCAATTCGCTGACTTTCAATGTTCTGTCAAAAGCCCGAGATTTGATGATG 660
 OY 861 CGTAAAGCTAGTCTGAAGCACTGCTATCTGACAGCTGACAGATTCACAGAT 920
 Db 661 CGTAAAGCTAGTCTGAAGCACTGCTATCTGACAGCTGACAGATTCACAGAT 720
 OY 921 CTGAGCTGATTTAAAGTGTCTCATATGACAGCCCTTGACAGGCTGTAAAGTATCA 980

Db 721 CTAGACTTGAATTAAGATGCTACATGACACCCCTTGACAGCGCTGCTAAGATTACA 780
 Qy 981 GTTGATTAAGATGACAGATTAATGTTGAAGTTCAGAGATTACAGACTATTGTAAC 1040
 Db 781 GTTGATTAAGATGACAGATTAATGTTGAAGTTCAGAGATTACAGACTATTGTAAC 840
 Qy 1041 CGATTGCTGATTAATTCGCAATTAGAAACACAACTTCTGACTTTGACCGTGAATAA 1100
 Db 841 CGATTGCTGATTAATTCGCAATTAGAAACACAACTTCTGACTTTGACCGTGAATAA 900
 Qy 1101 CTACAGACGTTGGCGAAATAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1160
 Db 901 CTACAGACGTTGGCGAAATAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 960
 Qy 1161 ACAGAGACGCTTTAAAGAAATGAACTTGCATGAGATGCTCTTAATGCTACAGCT 1220
 Db 961 ACAGAGACGCTTTAAAGAAATGAACTTGCATGAGATGCTCTTAATGCTACAGCT 1020
 Qy 1221 GCAGCGCTGTAAGAGATTAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1280
 Db 1021 GCAGCGCTGTAAGAGATTAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1080
 Qy 1281 AATGACAGCTCTGTGAGCTTGAGGCGATGATGCTACTGTGAGAGATGATGCTGCT 1340
 Db 1081 AATGACAGCTCTGTGAGCTTGAGGCGATGATGCTACTGTGAGAGATGATGCTGCT 1140
 Qy 1341 GCTCTAGAAAGCTGTGATGCTTAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1400
 Db 1141 GCTCTAGAAAGCTGTGATGCTTAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1200
 Qy 1401 AATGACAGCTCTGTGAGCTTGAGGCGATGATGCTACTGTGAGAGATGATGCTGCT 1460
 Db 1201 AATGACAGCTCTGTGAGCTTGAGGCGATGATGCTACTGTGAGAGATGATGCTGCT 1260
 Qy 1461 GTGATATGATTAAGAGATTAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1520
 Db 1261 GTGATATGATTAAGAGATTAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1320
 Qy 1521 AATGACAGCTCTGTGAGCTTGAGGCGATGATGCTACTGTGAGAGATGATGCTGCT 1580
 Db 1321 AATGACAGCTCTGTGAGCTTGAGGCGATGATGCTACTGTGAGAGATGATGCTGCT 1380
 Qy 1581 GAACAGCTGACGCGCCAGCAATGCGACAGATGATGCTGCGAATGATGCTGCG 1639
 Db 1381 GAACAGCTGACGCGCCAGCAATGCGACAGATGATGCTGCGAATGATGCTGCG 1439
 RESULT 4
 AAH56862
 ID AAH56862 standard: DNA: 1306 BP.
 AC AAH56862:
 DT 06-SEP-2001 (first entry)
 XX
 DE Antibiotic resistant S. pyogenes groEL gene partial sequence SEQ ID# 8.
 XX
 XX Antisense oligonucleotide: groEL; groEL; groEL; inhibitor; growth;
 KM microorganism: Escherichia coli; Streptococcus pneumoniae; diagnosis;
 KM Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
 KM antibacterial; antiviral; antiproliferative; antisense therapy;
 XX microbial infection; ds.
 OS Streptococcus pyogenes.
 XX
 PN W0200136625-A2.
 XX
 PD 25-MAY-2001.
 XX
 PF 20-NOV-2000: 2000MO-CA01347.
 XX
 PR 18-NOV-1999: 9905-0166249.
 XX

PA (GENE-) GENESENSE TECHNOLOGIES INC. 1
 XX
 PI Wright JA, Young AH, Dugourd D:
 XX
 DR WPI: 2001-355633/37.
 XX
 PT Novel antisense compounds targeting nucleic acid encoding groEL or
 PT groEL gene of microorganism, which hybridize with and inhibit
 PT expression of the genes, useful to inhibit growth of microorganism
 PT having the genes -
 PS
 PS Disclosure: Fig 8; 110pp: English.
 CC
 CC The present invention specifically claims AAH56368 to AAH56832 which are
 CC antisense oligonucleotides to nucleotide sequences encoding groEL. More
 CC generally, antisense compounds (I) comprising antisense oligonucleotides
 CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
 CC shock protein (HSP)60 (GL) and groES (HSP)10 (GS) gene from a
 CC microorganism, where the antisense compound is complementary to GL or
 CC GS of a microorganism and specifically hybridizes with and inhibits the
 CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral
 CC and antiproliferative activities, and can be used in antisense therapy
 CC and for inhibition of expression of groEL or groEL. (I) are useful for
 CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
 CC also useful for inhibiting the growth of a microorganism, or inhibiting
 CC the expression of GL or GS gene in a microorganism (a bacterial cell or
 CC a virus) having a GL or GS gene which involves administering to the
 CC microorganism or to a cell infected with the microorganism (I) (I) are
 CC also useful for treating a mammalian pathological condition mediated by
 CC the microorganisms which involves identifying a eukaryotic organism
 CC having a pathological condition mediated by microorganisms having a GL
 CC or GS gene and administering (I) such that the growth of microorganism
 CC is inhibited. The antisense compounds are utilized for diagnostics,
 CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
 CC prevent or delay microbial infections in humans. They are also useful as
 CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56834
 CC represent PCR primers for groEL sequences which are used in the
 CC exemplification of the present invention. AAH5655 to AAH56870 represent
 CC groEL nucleotide sequence given in the present invention.
 SO
 SO Sequence 1306 BP; 407 A; 235 C; 308 G; 356 T; 0 other;
 Query Match 68.7%; Score 1140.4; DB 22; Length 1306;
 Best Local Similarity 99.9%; Pred. No. 7.6e-289;
 Matches 1141; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 498 GAAGCTATGAGCGGTGTGGCAACGATGCTGATTAACATCGAAGATCGAGATG 557
 Db 2 GAAGCTATGAGCGGTGTGGCAACGATGCTGATTAACATCGAAGATCGAGATG 61
 Qy 558 GAACAGAACTTAAGTGTGAAGGATGATGATGATGATGATGATGATGATGATGATG 617
 Db 62 GAACAGAACTTAAGTGTGAAGGATGATGATGATGATGATGATGATGATGATGATG 121
 Qy 618 ATGCTCAGACAGCAATGAAAAATGCTGCAAGCTTGAAGCAATTAATCTTAATCAG 677
 Db 122 ATGCTCAGACAGCAATGAAAAATGCTGCAAGCTTGAAGCAATTAATCTTAATCAG 181
 Qy 678 GATTAAGAAAGTGTCAAAATCCCAAGACATTTGACACTAGTGAAGAGTTCTTAAGC 737
 Db 182 GATTAAGAAAGTGTCAAAATCCCAAGACATTTGACACTAGTGAAGAGTTCTTAAGC 241
 Qy 738 AACGCTCATTAATCAATTAATGAGATGATGATGATGATGATGATGATGATGATG 797
 Db 242 AACGCTCATTAATCAATTAATGAGATGATGATGATGATGATGATGATGATGATG 301
 Qy 798 TTGAACAGATTCGTGCTACTTTCATATGCTGCTCAAAAGCCGAGATTTGCTGAT 857
 Db 302 TTGAACAGATTCGTGCTACTTTCATATGCTGCTCAAAAGCCGAGATTTGCTGAT 361
 Qy 858 CGTGTAAAGCTATGCTGATGAGACATTTGATGACAGTGTGATGATGATGATGATG 917
 Db 362 CGTGTAAAGCTATGCTGATGAGACATTTGATGACAGTGTGATGATGATGATGATG 421

```

OY 918 GATGTAGAGCTTGAATTAAGATGCTACANTGACAGCCCTTGAGAGGCTGTAAGATT 977
    |||||||
Db 422 GATGTAGAGCTTGAATTAAGATGCTACANTGACAGCCCTTGAGAGGCTGTAAGATT 481
OY 978 ACAGTTGATAAAGATGACAGATTAATTTGTAAGAGTTCAGAGATTCAGAGCTTTGGT 1037
    |||||||
Db 482 ACAGTTGATAAAGATGACAGATTAATTTGTAAGAGTTCAGAGATTCAGAGCTTTGGT 541
OY 1038 AACCGTATGCACTGATTAATTCGCAATTAAGAAACAACTTGTGACTTTGACCGTGA 1097
    |||||||
Db 542 AACCGTATGCACTGATTAATTCGCAATTAAGAAACAACTTGTGACTTTGACCGTGA 601
OY 1098 AAACCTCAAGAACCTTTGGCGAAATTAAGCTGTGTGATAGCTTTATCAAGTAGAGACT 1157
    |||||||
Db 602 AAACCTCAAGAACCTTTGGCGAAATTAAGCTGTGTGATAGCTTTATCAAGTAGAGACT 661
OY 1158 CCAACAGACAGCTTTAAAGAAATGAACCTTCGATTTGAGATGCTTAAATGCTACA 1217
    |||||||
Db 662 CCAACAGACAGCTTTAAAGAAATGAACCTTCGATTTGAGATGCTTAAATGCTACA 721
OY 1218 CGTGCAGCCGTTGAGAGAGGTATCGTGTGCTGTGTGAGAGAGCACTTTATACGGTTATT 1277
    |||||||
Db 722 CGTGCAGCCGTTGAGAGAGGTATCGTGTGCTGTGTGAGAGAGCACTTTATACGGTTATT 781
OY 1278 GAAAAAGTAGAGAGCTTTGAGAGGAGGATGATGCTAGCTAGCTAGCTAGCTAGCT 1337
    |||||||
Db 782 GAAAAAGTAGAGAGCTTTGAGAGGAGGATGATGCTAGCTAGCTAGCTAGCTAGCT 841
OY 1338 CGTGCCTGAGAGAGCTGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCT 1397
    |||||||
Db 842 CGTGCCTGAGAGAGCTGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCT 901
OY 1398 GTTATGACAGCTGGAAGAAACCCCTGCGAGAGAGATTTAATCTGCAACAGGTGAG 1457
    |||||||
Db 902 GTTATGACAGCTGGAAGAAACCCCTGCGAGAGAGATTTAATCTGCAACAGGTGAG 961
OY 1458 TGGGTGATATGATTAAGACAGAAATCATGACCTGTCAAGATTAACAGATGAGCGCTT 1517
    |||||||
Db 962 TGGGTGATATGATTAAGACAGAAATCATGACCTGTCAAGATTAACAGATGAGCGCTT 1021
OY 1518 CAATATGACAGCTTGTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCT 1577
    |||||||
Db 1022 CAATATGACAGCTTGTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCT 1081
OY 1578 CCTGAACAGCTAGAGCCAGCCAGCAAGTCCAGAGAGTATGATCCAGAAATGATGGGT 1637
    |||||||
Db 1082 CCTGAACAGCTAGAGCCAGCCAGCAAGTCCAGAGAGTATGATCCAGAAATGATGGGT 1141
OY 1638 GG 1639
    ||
Db 1142 GG 1143

```

RESULT 5

AAH56865 standard; DNA; 1305 BP.

ID AAH56865;

06-SEP-2001 (first entry)

```

DE Antibiotic resistant S. pyogenes groEL gene partial sequence SEQ ID:11.
XX
XX Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth.
XX microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
XX Streptococcus pyogenes; Staphylococcus aureus; pseudomonas aeruginosa;
XX antibacterial; antiviral; antiproliferative; antisense therapy;
XX microbial infection; ds.
OS Streptococcus pyogenes.
XX
XX PN W0200136635-A2.

```

```

XX 25-MAY-2001.
XX
XX 20-NOV-2000; 2000MO-CA01347.
XX
XX 18-NOV-1999; 9905-0166249.
XX
XX (GENE-) GENESENSE TECHNOLOGIES INC.
XX
XX Wright JA, Young AH, Dugourd D;
XX WPI: 2001-355633/37.
XX
XX Novel antisense compounds targeting nucleic acid encoding groEL or
XX groES gene of microorganism, which hybridize with and inhibit
XX expression of the genes, useful to inhibit growth of microorganism
XX having the genes.
XX
XX Disclosure: Fig 11; 110pp; English.
XX
XX The present invention specifically claims AAH56368 to AAH56832 which are
XX antisense oligonucleotides to nucleotide sequences encoding groE. More
XX generally, antisense compounds (I) comprising antisense oligonucleotides
XX of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
XX shock protein (HSP)60) (G1) and groES (HSP10) (G2) gene from a
XX microorganism, where the antisense compound is complementary to G1 or
XX G2 of a microorganism and specifically hybridizes with and inhibits the
XX expression of G1 or G2, is claimed. (I) have antibacterial, antiviral
XX and antiproliferative activities, and can be used in antisense therapy
XX and for inhibition of expression of groES or groEL. (I) are useful for
XX inhibiting expression of G1 or G2 in cells or tissues in vitro. (I) are
XX also useful for inhibiting the growth of a microorganism, or inhibiting
XX the expression of G1 or G2 gene in a microorganism (a bacterial cell or
XX a virus) having a G1 or G2 gene which involves administering to the
XX microorganism or to a cell infected with the microorganism, (I). (I) are
XX also useful for treating a mammalian pathological condition mediated by
XX the microorganisms which involves identifying a eukaryotic organism
XX having a pathological condition mediated by microorganisms having a G1
XX or G2 gene and administering (I) such that the growth of microorganism
XX is inhibited. The antisense compounds are utilized for diagnostics,
XX therapeutics, prophylaxis and as research reagents and kits, e.g., to
XX prevent or delay microbial infections in humans. They are also useful as
XX molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
XX represent PCR primers for groE sequences which are used in the
XX exemplification of the present invention. AAH56855 to AAH56870 represent
XX groE nucleotide sequence given in the present invention.
XX
XX Sequence 1305 BP: 406 A; 238 C; 312 G; 349 T; 0 other:
XX
XX Query Match 67.6%; Score 1122.6; DB 22; Length 1305;
XX Best Local Similarity 99.2%; Pred. No. 3.6e-284;
XX Matches 1128; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
OY 503 TATGAGCGCTGTGGCAGAGATGTGTGATTACATCGAAGATCTCGAGTATGAAC 562
    |||||||
Db 1 TATGAGCGCTGTGGCAGAGATGTGTGATTACATCGAAGATCTCGAGTATGAAC 60
OY 563 AGAAGCTTGAAGTGTGAGGATGCAATTTGACCGTGTGATCTGCTCATATATAGT 622
    |||||||
Db 61 AGAAGCTTGAAGTGTGAGGATGCAATTTGACCGTGTGATCTGCTCATATATAGT 120
OY 623 CACAGCATATGAAAAAATGTTGCGAGACTTGAAGAAACCATTTATCTAATACGGATA 662
    |||||||
Db 121 CACAGCATATGAAAAAATGTTGCGAGACTTGAAGAAACCATTTATCTAATACGGATA 180
OY 663 AAAAGTGTCAACATCCAGACATTTTGCACATCTTGAGAGACTTCTTAAACCAACG 742
    |||||||
Db 181 AAAAGTGTCAACATCCAGACATTTTGCACATCTTGAGAGACTTCTTAAACCAACG 240
OY 743 TCCATTACTCATTTATGACAGATGATGTGATGTGTAAGCACTTCAACCCCTTGTGAA 802
    |||||||
Db 241 TCCATTACTCATTTATGACAGATGATGTGATGTGTAAGCACTTCAACCCCTTGTGAA 300

```


Best Local Similarity 79.2%, Pred. No. 2.4e-268;
Matches 1274; Conservative 0; Mismatches 331; Indels 3; Gaps 1;

```

Oy 15 ATGGCAAAAGAAATCAATTTTTCAGACAGATGCGCGTCTGCTCCATGCTGCGCGAGATTGAT 74
Db 1 ATGGCAAAAGAAATTTAAATTTTCAGACAGATGCGCGTCTGCTCCATGCTGCGCGAGATTGAT 60
Oy 75 ATTTTACGAGATACCGTCAAGTAAAGCTTGTCTTAAAGGGCGCAATGTTGCTTGA 134
Db 61 ATTTTACGATACGATCAAGTAAAGTATAGTCTTAAAGGGCGCAATGTTGCTTGA 120
Oy 135 AAAGCTTTGGTCTCCCTTAATTAATGACGGGCTAACCATGCTTAAGATCGAA 194
Db 121 AAAGCATTTGGTCTCCCTTAATTAATGACGGGCTAACCATGCTTAAGATCGAA 180
Oy 195 TTGAAGATCATTTTGAACATGAGAGCAAAATGCTGTCTGAAGTGGCTCTAAAGC 254
Db 181 CTGAAGATCATTTTGAACATGAGAGCTAAACTGTGTCAAGATGGCTCTAAAGC 240
Oy 255 AATGATTTGCTGTGATGGAGACACTACGCAAGATTTGACAGACCCATTGTCAT 314
Db 241 AATGATTTGAGGGATGGAGACACTACGCTACTGTTTGAAGCCAGCTATTTGTACG 300
Oy 315 GAAGCACTAAAAATGTGACAGCAGTGTCAATCCAAATGATTCGTCGAGGCAATTGA 374
Db 301 GAAGCTCTTAAAAATGTAACTGAGGGCAAAATCGAATGGCAATTCGTCGATTTGA 360
Oy 375 ACAGCAACGCAACAGCTGTGAAAGCCCTGAAAGCCATTGCTACAGCTATTCGCAAG 434
Db 361 ACAGCTGTTTACAGCAGCTGTGAAAGCCCTGAAAGCCATTGCTACAGCTTACAGCAA 420
Oy 435 GAAGCTATTGCTGAGTGTGCTGAGTATCATCAGCTGTGAAAGATTTGGAGATTAATC 494
Db 421 GAAGCTATTGCTGAGTGTGCTGAGTATCATCAGCTGTGAAAGATTTGGAGATTAATC 480
Oy 495 TCAGAAAGCTATGAGAGGCTGTGGCAAGATGCTGATACCTGCAAGATTCGCAAG 554
Db 481 TCTGAAGCTATGAGAGGCTGTGGCAAGATGCTGATACCTGCAAGATTCGCAAG 540
Oy 555 ATGSAACAGAACTGAAAGCTGTGAAGCATTCATTTGACCGTGTGCTGCTGCTCA 614
Db 541 ATGSAACAGAACTGTGAAGCTGTGAAGCATTCATTTGACCGTGTGCTGCTGCTCA 600
Oy 615 TACATGCTACAGACATGAAAAATGGTTGCAGACTGAAACCCATTATCTTAATC 674
Db 601 TATATGCTACAGACATGAAAAATGGTTGCAGACTGAAACCCATTATCTTAATC 660
Oy 675 ACGGATAAAAGTGTCAAAACATCCAGACATTCCTGCTACTTGTAGAGATTTCTTAA 734
Db 661 ACGGATAAAAGTGTCAAAACATCCAGACATTCCTGCTACTTGTAGAGATTTCTTAA 720
Oy 735 ACCAAGCTGCATTATCATTTATGAGATGATGATGATGATGATGATGATGATGAT 794
Db 721 ACAAACTGCCTGCTATCATCTGATGATGATGATGATGATGATGATGATGATGAT 780
Oy 795 GTCTTGAACAAAGTGTGCTGATCTTCAATGCTGTGCTGCTGCTGCTGCTGCTGCT 854
Db 781 GTCTTGAACAAAGTGTGCTGATCTTCAATGCTGTGCTGCTGCTGCTGCTGCTGCT 840
Oy 855 GATGCTGTAAAGCTATGCTGAAAGCATTCGCTGCTGCTGCTGCTGCTGCTGCTGCT 914
Db 841 GATGCTGTAAAGCTATGCTGAAAGCATTCGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
Oy 915 GAGATCTAGAGCTGATTTAAAGATGCTACATGACAGCCCTGGACAGGCTGTAAG 974
Db 901 GAAGCTGTGCTTGTAGCTTAAAGATGCTACATGATTTGAGCAGCTGTGTAAG 960
Oy 975 ATTAAGCTGATTAAGATGACAGATTAATGTTGTAAGCTGACAGATTCGTAAG 1034
Db 961 GTAAAGCTGATTAAGATTTCTGTTATGCTGTAAGCTGACAGATTCGTAAG 1020
Oy 1035 GCTAAAGCTGATTAAGATTAATGCAATTAAGCAAACTTGTGACTTGTGACCT 1094
Db 1021 GCTAATGCGTATGATTAATGATGACAGATGAGGCTACAACTTGTGATTTGATGCT 1080
Oy 1095 GAAAACTACAGAAAGCTTTGGCGAAATTAAGCTGTGATGCTGATTAACAAAGTAGA 1154
Db 1081 GAAAAATTTACAGAAAGCTTTGCTAAGTATGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
Oy 1155 GCTCAACAGAGACAGCTTTTAAAGAAATGCAATGCTGATGATGATGATGATGATGAT 1214
Db 1141 GCAGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1200
Oy 1215 ACAGCTGAGGCGCTGAAAGAGTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1274
Db 1201 ACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
Oy 1275 ATGAAAAAGTATGACAGCTCTTGACCTTGAGGCGATGATGCTACTGAGCTAACTGTG 1334
Db 1261 ATGAAAAAGTATGACAGCTCTTGACCTTGAGGCGATGATGCTACTGAGCTAACTGTG 1320
Oy 1335 CTTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1394
Db 1321 CTTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
Oy 1395 GTAGTATTTGACAGCTTGAAGAAAGAGCCCTGACAGAAAGATTAATGCTGCAACAGT 1454
Db 1381 GTATATTTGACAGCTTGAAGAAAGAGCTGCAATTTGATGATGATGATGATGATGATGAT 1440
Oy 1455 GAGTGGTGTATGATTAATTAAGAGATGATGATGATGATGATGATGATGATGATGATGAT 1514
Db 1441 GAATGGTGTATGATTAATTAAGAGATGATGATGATGATGATGATGATGATGATGATGAT 1500
Oy 1515 CTTCAAAATGACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1574
Db 1501 CTTCAAAATGACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1560
Oy 1575 AAACCTGAAC---AGCTACGCGACGCGACAGCAATCCAGAGATGATG 1619
Db 1561 AAACCTGAACGAGAGCTCTACAGCTCTGCAATGATGATGATGATGATGATGATGATGAT 1608

RESULT 8
AA86153
ID AA86153 standard; DNA; 1654 BP.
XX
AC AA86153;
XX
DT 22-SEP-1999 (first entry)
XX
DE DNA encoding a Streptococcus pneumoniae heat shock protein (Hsp)60-2.
XX
KW Heat shock protein; Hsp60-2; Immune response; Immunological carrier;
XX
KW cancer control; tumour; sarcoma; cancer; gene therapy; sf.
XX
OS Streptococcus pneumoniae.
XX
PN M09935270-A1.
XX
PD 15-JUL-1999.
XX
PF 29-DEC-1998; 98MO-CA01203.
XX
PR 31-DEC-1997; 97US-0001737.
XX
PA (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.
XX
PI Mizzen L, Wisniewski J;
XX
DR WPI: 1999-430397/36.
XX
DR P-PSDB: AAY23902.
XX
PT New nucleic acid encoding heat shock protein-60 from Streptococcus,
XX
PT useful in vaccines, as carriers for other immunogens, as anticancer
XX
PT agents and for diagnosis

```

PS Claim 3; Fig 2a-b: 176bp; English.

XX The present sequence encodes a heat shock protein, designated Hsp60-2.

CC The protein, its fragments, variants and fusion proteins, are

CC used to elicit or enhance an immune response against Streptococcus,

CC and to elicit a similar response to a target antigen fused to the

CC protein. Unlike other immunological carriers, Hsp60 proteins are not

CC immunosuppressive so provide an increased response to any conjugated or

CC fused antigen. Also, where used for cancer control, they lack the side

CC effects associated with endotoxins. They can also be used to detect

CC specific antibodies and in treatment or prevention of tumours

CC (e.g. sarcoma or cancers of breast, ovary, prostate, lung, pancreas or

CC liver). The Hsp60 polynucleotide is used for recombinant production

CC of the protein, as a source of primers and probes for detecting

CC streptococci in standard hybridization/amplicon assays, and

CC therapeutically in gene therapy vectors.

XX

Sequence 1654 bp: 500 A; 326 C; 401 G; 427 T; 0 other:

Query Match 63.3%; Score 1052; DB 20; Length 1654;

Best Local Similarity 77.7%; Fred. No. 1.3e-265;

Matches 1271; Conservative 0; Mismatches 365; Indels 0; Gaps 0;

XX 1 GAATGCGCTTCATATGCGCAAAAGAAATCAATTTTACAGCATGCGCGTGGCCATGG 60

DB 1 GAATGCGCTTCATATGCGCAAAAGAAATCAATTTTACAGCATGCGCGTGGCCATGG 60

XX 61 TCGCGGAGTGTGATATGTAGCAGATACCGTCAAGCTGTGCTTAAGGGGCGCA 120

DB 61 TCGCGGAGTGTGATATGTAGCAGATACCGTCAAGCTGTGCTTAAGGGGCGCA 120

XX 121 ATGTTGTTCTGAAAAAGCTTTTGGTCTCCCTTAATTAATTAAGAGGGGATACATG 180

DB 121 ATGTTGTTCTGAAAAAGCTTTTGGTCTCCCTTAATTAATTAAGAGGGGATACATG 180

XX 121 ATGCTGTTCTGAAAAAGCTTTGCTGCTTATCCATTAATTAAGAGGGGATACATG 180

DB 121 ATGCTGTTCTGAAAAAGCTTTGCTGCTTATCCATTAATTAAGAGGGGATACATG 180

XX 181 CTAAAGATGATTAAGAAATGATTTTGAAGAAATGGGCAAAATTTGGCTGTAG 240

DB 181 CTAAAGATGATTAAGAAATGATTTTGAAGAAATGGGCAAAATTTGGCTGTAG 240

XX 181 CCAAAATATGATTAAGAAATGATTTTGAAGAAATGGGCAAAATTTGGCTGTAG 240

DB 181 CCAAAATATGATTAAGAAATGATTTTGAAGAAATGGGCAAAATTTGGCTGTAG 240

XX 241 TGCTCTTAAGCAATGATTTGCTGTATGCGCACTACTGCAAGATTTTGAC 300

DB 241 TGCTCTTAAGCAATGATTTGCTGTATGCGCACTACTGCAAGATTTTGAC 300

XX 241 TACCTTCAAAACCAATGATTTGCTGTATGCGCACTACTGCAAGATTTTGAC 300

DB 241 TACCTTCAAAACCAATGATTTGCTGTATGCGCACTACTGCAAGATTTTGAC 300

XX 301 AAGCATTGTTGATGAGCACTAAATTTGACAGCAGGTGCTAATGATTTGAC 360

DB 301 AAGCATTGTTGATGAGCACTAAATTTGACAGCAGGTGCTAATGATTTGAC 360

XX 301 AAGCAATGCTGCGTGAAGCAATCAAAACGTCACAGCAGGTGCAAAATGCGTATTC 360

DB 301 AAGCAATGCTGCGTGAAGCAATCAAAACGTCACAGCAGGTGCAAAATGCGTATTC 360

XX 361 GTCGAGGCAATTAAGCAAGCAAGCAAGCTTTGAAGCCTTGAAGCATTGCTGAC 420

DB 361 GTCGAGGCAATTAAGCAAGCAAGCAAGCTTTGAAGCCTTGAAGCATTGCTGAC 420

XX 361 GTCGAGGCAATTAAGCAAGCAAGCAAGCTTTGAAGCCTTGAAGCATTGCTGAC 420

DB 361 GTCGAGGCAATTAAGCAAGCAAGCAAGCTTTGAAGCCTTGAAGCATTGCTGAC 420

XX 421 CTGATCTGCGCAAGAGCTATTTGCTGAGCGCTGAGTATCAACGCTGTGAAAAG 480

DB 421 CTGATCTGCGCAAGAGCTATTTGCTGAGCGCTGAGTATCAACGCTGTGAAAAG 480

XX 421 CTGATCTGCGCAAGAGCTATTTGCTGAGCGCTGAGTATCAACGCTGTGAAAAG 480

DB 421 CTGATCTGCGCAAGAGCTATTTGCTGAGCGCTGAGTATCAACGCTGTGAAAAG 480

XX 481 TTGAGAGATATATCTGAGAAAGCTATGAGCGGTGGCAAGATGCTGATTCATCG 540

DB 481 TTGAGAGATATATCTGAGAAAGCTATGAGCGGTGGCAAGATGCTGATTCATCG 540

XX 481 TTGAGAGATATATCTGAGAAAGCTATGAGCGGTGGCAAGATGCTGATTCATCG 540

DB 481 TTGAGAGATATATCTGAGAAAGCTATGAGCGGTGGCAAGATGCTGATTCATCG 540

XX 541 AAGATATCTGAGATGAGAAAGCAAGCTGAGTGTGAAGGATGCAATTTGACGCTG 600

DB 541 AAGATATCTGAGATGAGAAAGCAAGCTGAGTGTGAAGGATGCAATTTGACGCTG 600

XX 541 AAGATATCTGAGATGAGAAAGCAAGCTGAGTGTGAAGGATGCAATTTGACGCTG 600

DB 541 AAGATATCTGAGATGAGAAAGCAAGCTGAGTGTGAAGGATGCAATTTGACGCTG 600

XX 601 GTTACCTGCTCATATACATGCTCACAGCAATGAAAAATGTTGACAGCTTGAAGC 660

DB 601 GTTACCTGCTCATATACATGCTCACAGCAATGAAAAATGTTGACAGCTTGAAGC 660

XX 601 GTTACCTGCTCATATACATGCTCACAGCAATGAAAAATGTTGACAGCTTGAAGC 660

DB 601 GTTACCTGCTCATATACATGCTCACAGCAATGAAAAATGTTGACAGCTTGAAGC 660

XX 661 CATTTATCTATACAGGATTAAGAAAGTGCACAACTCAAGCAATTTGCCACTGTTG 720

DB 661 CATTTATCTATACAGGATTAAGAAAGTGCACAACTCAAGCAATTTGCCACTGTTG 720

XX 661 CATTTATCTATACAGGATTAAGAAAGTGCACAACTCAAGCAATTTGCCACTGTTG 720

DB 661 CATTTATCTATACAGGATTAAGAAAGTGCACAACTCAAGCAATTTGCCACTGTTG 720

XX 721 AGGAGTCTTAAGCAAGCCTCATCTACTGATTAATGAGATGATGATGATGATG 780

DB 721 AGGAGTCTTAAGCAAGCCTCATCTACTGATTAATGAGATGATGATGATGATGATG 780

XX 721 AGGAGTCTTAAGCAAGCCTCATCTACTGATTAATGAGATGATGATGATGATGATG 780

DB 721 AGGAGTCTTAAGCAAGCCTCATCTACTGATTAATGAGATGATGATGATGATGATG 780

DB 721 AAGGATCTTCCAAAGCAATGCTCCACTTGTATTTGGGATGATGATGATGATG 780

XX 781 CACTTCCAACTGCTGCTTGAAGCAAGATTTGCTGATTTCAATGATGCTGCTGAAG 840

DB 781 CACTTCCAACTGCTGCTTGAAGCAAGATTTGCTGATTTCAATGATGCTGCTGAAG 840

XX 841 CCCCAGGATTTGGTGTGCTGTAAGCAATGCTTGAAGCAATGCTTGAAGCAATG 900

DB 841 CCCCAGGATTTGGTGTGCTGTAAGCAATGCTTGAAGCAATGCTTGAAGCAATG 900

XX 841 CACCTGCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 900

DB 841 CACCTGCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 900

XX 901 GTACAGATATACAGGATATGAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTG 960

DB 901 GTACAGATATACAGGATATGAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTG 960

XX 901 GTACAGATATACAGGATATGAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTG 960

DB 901 GTACAGATATACAGGATATGAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTG 960

XX 961 GACAGGCTGCTAAGATTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1020

DB 961 GACAGGCTGCTAAGATTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1020

XX 961 GACAGGCTGCTAAGATTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1020

DB 961 GACAGGCTGCTAAGATTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1020

XX 1021 GTTCAAGAGCTATTTGCTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1080

DB 1021 GTTCAAGAGCTATTTGCTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1080

XX 1021 GTTCAAGAGCTATTTGCTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1080

DB 1021 GTTCAAGAGCTATTTGCTAAGCTGATTAAGCAATGCTGCTGCTGCTGCTGCTGCTG 1080

XX 1081 CTGACTTTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140

DB 1081 CTGACTTTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140

XX 1081 CTGACTTTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140

DB 1081 CTGACTTTGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140

XX 1141 TTATCAAGATGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200

DB 1141 TTATCAAGATGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200

XX 1141 TTATCAAGATGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200

DB 1141 TTATCAAGATGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200

XX 1201 ATGCTCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260

DB 1201 ATGCTCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260

XX 1201 ATGCTCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260

DB 1201 ATGCTCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260

XX 1261 CACTTATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320

DB 1261 CACTTATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320

XX 1261 CACTTATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320

DB 1261 CACTTATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320

XX 1321 GACCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380

DB 1321 GACCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380

XX 1321 GACCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380

DB 1321 GACCTTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380

XX 1381 GGTACGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440

DB 1381 GGTACGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440

XX 1381 GGTACGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440

DB 1381 GGTACGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440

XX 1441 ATGCTGCAAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500

DB 1441 ATGCTGCAAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500

XX 1441 ATGCTGCAAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500

DB 1441 ATGCTGCAAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500

XX 1501 TGAATCTTGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560

DB 1501 TGAATCTTGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560

XX 1501 TGAATCTTGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560

DB 1501 TGAATCTTGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560

XX 1561 CAGTGTGCTAATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1620

DB 1561 CAGTGTGCTAATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1620

XX 1561 CAGTGTGCTAATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1620

DB 1561 CAGTGTGCTAATTAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1620

XX 1621 ATCCAGATGATGAGG 1636

DB 1621 ATCCAGATGATGAGG 1636

XX 1621 ATCCAGATGATGAGG 1636

DB 1621 ATCCAGATGATGAGG 1636

XX 1621 TGCGTGAATGGGCGG 1636

DB 1621 TGCGTGAATGGGCGG 1636

XX 1621 TGCGTGAATGGGCGG 1636

DB 1621 TGCGTGAATGGGCGG 1636

RESULT 9

AAH90800

ID AAH90800 standard. DNA: 1623 bp.

XX

AC AAH90800;

XX

DT 02-OCT-2001 (first entry)

XX

DE CFE 104 coding sequence.

XX

KW Antibacterial; vaccine; gene therapy; bacterial cell wall viability;
 KW CPE; CEG; Conserved Essential Gene; bacterial infection;
 KW antisense therapy; antibiotic resistance; ds.
 OS Streptococcus pneumoniae.
 PN WO200149721-A2.
 XX 12-JUL-2001.
 PD 29-DEC-2000; 2000MO-US35604.
 PF 30-DEC-1999; 99US-0174089.
 PR (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA Dougherty JV, Pucci MJ, Dougherty BA, Davison DB, Brucoleri RE;
 PI Thamsai JA;
 DR WPI: 2001-496721/54.
 XX P-PSDB; AAM01101.
 PT Nucleic acids encoding conserved essential genes involved in bacterial
 PT replication which are potential targets for the treatment of antibiotic
 PT resistant bacterial infections -
 XX
 PS Claim 16; Page 231; 380pp; English.
 XX The present invention relates to nucleic acids (AAH90701-AAH90918)
 CC encoding polypeptides (AAM01002-AAM0114), which are essential for the
 CC viability of a bacterial cell wall. The acronym CPE stands for "CEG For
 CC Expression", where CEG stands for "Conserved Essential Gene". The nucleic
 CC acids are useful for detecting the presence of proteins essential for the
 CC viability of a bacterial cell wall in samples such as cells, tissues,
 CC biological fluids, blood, serum, nose, ear or throat swabs with ligands,
 CC and for detecting corresponding target nucleic acid molecules with
 CC complementary sequences. The nucleic acids are also useful for
 CC determining whether a genomic nucleotide sequence of interest is
 CC essential for viability of a bacterial cell or whether it resides within
 CC an operon, by integrating an exogenous nucleotide sequence comprising a
 CC portion of an open reading frame of the genomic sequence of interest
 CC (comprising 200-500 base pairs) into the genomic sequence of interest
 CC which confers a selectable phenotype to the cell, and determining cell
 CC viability with a selection agent such as chloramphenicol. The nucleic
 CC acids and proteins are also useful as vaccines and for treating bacterial
 CC infections with gene therapy and antisense therapy. The nucleic acids
 CC also enable identification of targets suitable for the treatment of
 CC antibiotic resistant bacterial infections.
 CC
 XX Sequence 1623 BP; 490 A; 325 C; 394 G; 414 T; 0 other;
 SO
 Query Match 62.6%; Score 1039.2; DB 22; Length 1623;
 Best Local Similarity 77.6%; Pred. No. 2,9e-262;
 Matches 1257; Conservative 0; Mismatches 363; Indels 0; Gaps 0;

Db 241 AATGATATTCGAGGTGAGGAGCACTACGATGCAACAGTCTTGACCCCAAGCATTCGTCCT 300
 Qy 315 GAAGAGCTAAAAATGTGACACGACGTCGTATCAATGATGATGTCGAGCATTGAA 374
 Db 301 GAAGGATCTAAAAAGCTCACAGCAGGTGCAAAATCCATGGTATTCGTCGGATTGAA 360
 Qy 375 ACAGCAACGACAGCAGCTGTGAACCTGTGAAGCCATTCAGCTATCTGCGCAAG 434
 Db 361 ACAGCAGTTCGCCGACGAGCTGAACCTTGAACCAACAGCAGTCCCTTCCTCCATRAA 420
 Qy 435 GAAGCTATTCGTCAGTCGCTGCAAGTATCAATCACTGCAAAAAGTGGAGATATATG 494
 Db 421 GAAGCATTCGCTCAAGTTCGACAGATATCTTCCTGCTTGAAAGTGGTAGACATC 480
 Qy 495 TCAGAACTATGAGCGCTGTGGCAAGATGCTGTGATTAACATCAAGATCTCGAGGT 554
 Db 481 TCTGAGCAATGGAAAAAGTGGCAAGACGCTGATCAACATCAAGATCAAGATCGTGT 540
 Qy 555 ATGGAACAGAACTGAGTGGTGAAGGCATCAATTTGACCGTGTACCTGTCA 614
 Db 541 ATGGAACAGAACTTTCGAACATCCAGAAATCTTGCCACTTTGGAAAGCATTCGCA 600
 Qy 615 TACATGCTCAGACGCAATGAAAAATGTTGACAGCTTGAAAAACCATTAATCTTATATC 674
 Db 601 TACATGCTGACAGATGAGCAAAAATGCTGACCTTGAAAAATCCGTACATTTTGAT 660
 Qy 675 ACGATAAAAAAGTGTCAACATCCAGACATTTTGGCACTAGTGAAGTCTTAA 734
 Db 661 ACAGCAAGAAATTTCCAAATCCAGAAATCTTGCCACTTTGGAAAGCATTCGCA 720
 Qy 735 ACCAAGCTGCATTAATCAATTTGAGATGAGATGAGATGAGATGAGATGAGATGAGAT 794
 Db 721 AGCAATCTCCACTCTGATTTTTCGAGATGAGATGAGATGAGATGAGATGAGATGAGAT 780
 Qy 795 GCTTGAACAAAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 854
 Db 781 GTTTGAACAAAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 840
 Qy 855 GATCGCTAAACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 914
 Db 841 GACCTGTCAACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
 Qy 915 GAGGATCTAGACCTGATTAATTAAGATGATGATGATGATGATGATGATGATGATGATGAT 974
 Db 901 GAGGATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
 Qy 975 ATTACAGTATTAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1034
 Db 961 GTGACCTGTGACAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1020
 Qy 1035 GCTAACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1094
 Db 1021 TCTGACGCTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1080
 Qy 1095 GAAAAAATCAACAAAGCTTGGCAATTAAGTGTGATGATGATGATGATGATGATGATGATGAT 1154
 Db 1081 GAAAAAATGCAACAAAGCTTGGCAATTAAGTGTGATGATGATGATGATGATGATGATGATGAT 1140
 Qy 1155 GCTCCACAGACAGCTTTAAAAAAGATGAAATGCAATTCGATAGAGATGCTTAATGCT 1214
 Db 1141 GCGGCACTAAACAGATGATGAAAGAAATGAAATGCAATTCGATAGAGATGCTTAATGCT 1200
 Qy 1215 ACACGTGACCCCTTGAAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1274
 Db 1201 ACTGCTGACCTGTTGAAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1260
 Qy 1275 ATTGAAAAAATGACAGCTTGAAGCTTGAAGAGATGATGATGATGATGATGATGATGATGAT 1334
 Db 1261 ATTCCAGCTGTTCTACCTTGAATGACAGAGATGATGATGATGATGATGATGATGATGATGAT 1320
 Qy 1335 CTTCGCTCTAGAGAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1394
 Db 1321 CTCGCTGTTGAGAGACCGCTTCGTAATTCGTAATTCGTAATTCGTAATTCGTAATTCGTAAT 1380

XX	Sequence	1926 BP; 585 A; 382 C; 464 G; 495 T; 0 other;
SQL	Query Match	62.5%; Score 1038.4; DB 22; Length 1926;
	Best Local Similarity	77.5%; Pred. No. 56-272;
	Matches 1258; Conservative	0; Mismatches 366; Indels 0; Gaps 0;
QY	15	ATGGCAAAAGAAATCAAAATTTTCAGCAAGATGCGCGTCCGCAATGCGGCGGAGACTGAT 74
DB	1	ATGGCAAAAGAAATTTAAATTTTCATCATCATGATCCCGTTCAGCTATGCGTGGTGTGAT 60
QY	75	ATGCTTACGAGATACCGTCAAAGTAACCGTTGCTCTAAAGGGCCCAATGTTGTTCTGAA 134
DB	61	ATCTTTCAGATACACTGTTAAAGTAAGTAAGTAAGTAAGTAAGTAAGTAAGTAAGTAAGTA 120
QY	135	AAAGCTTTGGTCTCCCTTAATTTCTAATGACGGGTAAACCATTTGCTAAAGAGATGAA 194
DB	121	AAGCATATGGGTACACCTTTGATACCAATGACGGGTGATCATTATTCGCAAAAGTAATGAA 180
QY	195	TTAGAAATCATTTTGAAGAAACATGGGACCAAAATTTGGTGTCTGAAGTGGCTTTCTAAAC 254
DB	181	TTAAAGACCAATTTTGAAGTAATTTGGGTGCCAAATTTGATCAGAAATGACTTCATTAAC 240
QY	255	AATGATATTTGGTGTGATGGGAGACACTCTGTCGCAAGTTTGAACACAGCTTTGTCAT 314
DB	241	AATGATATGCGAGTGTGATGCACTCACTGCAACGTTTGGACCAAGCATTCCTCGT 300
QY	315	GAAAGCACTTAAATAATGTGACAGAGAGGTCTATATCAATTTGGATTCGCTGAGACATGAA 374
DB	301	GAAAGCATCAAAAACGTCAAGAGGTGCAAAATTCGAATGGATATGCTGTGGATGAA 360
QY	375	ACACAAACGCAACAGCTGTGTAAGCTTTGAAGCCATTTGCTCAACCTGATCTGGCAAG 434
DB	361	ACACAGCTTCCCGCAGCAGTGTAAACCTTTGAAAACAGTCATCCTTGTCCCAATAA 420
QY	435	GAAAGCTTTGCTCAGGTGCGTGCATATCATCAACGCTGTGAAAAGTTGGAAGATATTC 494
DB	421	GAACTTCTGCTCAAGTGTGAGCGCTATCTTCTGCTTCTGAAAAGTTGTTAGATATTC 480
QY	495	TCAAGAGCTATGAGCGTGTGGGACAGCATGTGTGATTTACCATCGAAGAAATCTCGAGT 554
DB	481	TCGGAAGCATGTGAAAAGTTGTGGCAAAACGGGTGTATCACCATCAAGAAAGCAAGTGT 540
QY	555	ATGGAACAGAACTTGAAGTGTGTGAAGCATCAATTTGACCGCTGTACTGTCTCAA 614
DB	541	ATGGAACAGCACTTGAAGTGTGTGAAGCATCAATTTGACCGCTGTACTGTCTCAA 600
QY	615	TACATGCTACAGCAATCAAAATTTGGTTGACAGACTTGAAGAACCCATTTATCTATATC 674
DB	601	TACATGCTACAGATATAGCAAAATTTGGTGGTGAACCTTGAATATCCGTATCTTTGAT 660
QY	675	ACGGAATAAATAAGTGTCAAAACATCCAGACATTTTCCACACTGTGAGAAATTTCTTAA 734
DB	661	ACGGAATAAATAATTTCCAAATTTCCAAAGAAATTTTCCACTTTTGGAAAGCATCTCCAA 720
QY	735	ACCAACCGTCCATTAATCAATTTTGCAGATGATGTAATGGTGAAGACTTCAACCCCT 794
DB	721	AGCAATCTGCCACTTTGATTTATTCGCGATGATGTGATGGTGAAGGCTTTTCCAACTTT 780
QY	795	GTCCTAAACAGATTTGCTGTCACTTCAATGATGCTGTCTGTCAACAGCGCAGATTTGGT 854
DB	781	GTTTATACAGATTTCTGGAACCTTCAAGCTGTATGCAAGTGAAGGACCTGTGTTGGT 840
QY	855	GATCTGTCTGAAGCTATGCTTAAGACATTTGCTATCTTGCAGAGTGTACAGTATGATCA 914
DB	841	GACGCTGCGAAGCAATGCTCTTAAGATATGCGCATCTTTAACAGGCGGAACATTTATACA 900
QY	915	GAGATCTTGAAGACTTGAATTAAGATGCTCAATGATACAGCCCTTGGACAGGCTGTCAAG 974
DB	901	GAGACCTTTGGCTTTGAGTTGAAGATGCGACAAATTTGAAGCTCTTGCTCAACAGCAGA 960
QY	975	ATTATCAGTTGATTAAGATAGCAACATTAATTTGTTGAAGGTTTACGAAAGTTCAGAGCAT 1034

Wed Apr 16 08:05:36 2003

us-09-001-737-7.rng

Page 13

Dp	961	GTGACGCGTGGACAAAGATAGCAAGCGTTATTGTGAAAGGTGCAAGAAATCTGAAAGCAATT	1020
Oy	1035	GCATACCGTATGACACTGATTAAATGCCATTTAGAAACAAACCTTGACTTTGACCGT	1094
Dp	1021	TCTCACCGTGTGGGTATCTCAATGTCTCAAAATGCAACTCAACTCTGCAATTTTGACCGT	1080
Oy	1095	GAAGAACTACAGACAGCTTTGGCCAAATTACGTGGTGGTGTACTGTTATCAAAATGACA	1154
Dp	1081	GAAGAAATTGCAAGAACGCTTTGGTGGCCAAATTGTGAGGTGGTGTATACCGTTATTAAAGTCGGA	1140
Oy	1155	GCTGCCACAGAGACAGCTTTAAAGAAATGAACACTGCAATTGAGATAGCTCTAAATGCT	1214
Dp	1141	GCCGGCAACATGAAACTAGTTGAAGAAATGAAGAACTCCGCAATTGAAGATGCCCTCACGCT	1200
Oy	1215	ACACGTGACGCGCTTGAAGAAAGTATCGTGTGGTGGTGGAAAGCAGCACTATTACGGTT	1274
Dp	1201	ACGTGTGAGCGTTGTAAAGAAAGTATGTGTGACAGTGGTGGAAACGCTTTGCCAATGTG	1260
Oy	1275	ATTGGAAGAAATACACAGCTCTTGAGCTTTGAGGGCATGTATGCTATCGACGTAACATTGTG	1334
Dp	1261	ATTCCAGCTGTGTCTACCTTGGAAATGACAGGAAGATGAACCAACAGGACGAATATTGTT	1320
Oy	1335	CTTTCGTGCTCTAGAGAGACCTGTACGCTCAAAATTGCTTTAAATGTCGGGTACGAGGCTCC	1394
Dp	1321	CTGCCCTGTTTGGAGAAACCGTGTCTCAAAATGCTCACAAAGCAGGATTTTGAAGGACT	1380
Oy	1395	GTAGTTATTGACAAAGTTGAAAAAACACCCCTGACGAGAACAGATTAATACGCGAAGAT	1454
Dp	1381	ATCGTTATTCATCGTTTAAAAAATGCTGAGCTGGTGTATAGATCAAGCGCAACGTGCG	1440
Oy	1455	GAGTGGGTATTTGATTTAAACAGCAATCATTAACCCGTGAAGATGAACAGATCACG	1514
Dp	1441	GAGTGGGTAACTGTTTGAATCAAGGTATCATCTATATCAAGTTAAAGTGAAGCTTCACG	1500
Oy	1515	CTTCAAAATGACAGCTTCTGTAGGTAACTCTATTTTGAACAAGAAAGCAAGTTGTGCTAAT	1574
Dp	1501	CTACAAATTCAGACATCTGTATGCCACACTGATTAATTTTGCAACAGAAAGCAGTCGTAGGCAT	1560
Oy	1575	AAACCTCAACACAGCTACGCCACGGCCAGCAATGCCAGACAGATATGATCCAGGAATGATG	1634
Dp	1561	AAACCAACACAGCTAGCCCAAGCTCCAGCAATGATCAAGATATGATGAGGTGCAATGGCG	1620
Oy	1635	GGTG 1638	
Dp	1621	GGAG 1624	

RESULT 11	ID	AAH56860	AAH56860 standard; DNA, 2107 BP.
AC	AAH56860;		
DT	06-SEP-2001	(first entry)	
DE	Antibiotic resistant S. pneumoniae groE operon sequence SEQ ID NO:6.		
XX			
XX	Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;		
XX	microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;		
XX	Streptococcus pyogenes; staphylococcus aureus; pseudomonas aeruginosa		
XX	antibacterial; antiviral; antiproliferative; antisense therapy;		
XX	microbial infection; ds.		
XX			
OS	Streptococcus pneumoniae.		
PN	XX		
PN	WO200136625-A2.		
XX			
PD	25-MAY-2001.		
XX			
PF	20-NOV-2000; 2000WO-CA01347.		
XX			
PR	18-NOV-1999; 99US-0166249.		
XX			

PA (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI Wright JA, Young AH, Dugourd D:
XX
DR WPI: 2001-355633/37.
XX
XX Novel antisense compounds targeting nucleic acid encoding groEL or
PT gross gene of microorganism, which hybridize with and inhibit
PT expression of the genes, useful to inhibit growth of microorganism
PT having the genes -
XX
XX Disclosure: Fig 6; 110pp. English.

Sequence 2107 BP; 650 A; 400 C; 508 G; 549 T; 0 other;

Query Match	62.48;	Score 1037;	DB 22;	Length 2107;
Best Local Similarity	77.58;	Pred. No. 1,2e-261;		
Matches 1265: Conservative	0.00	Missed 265		

QY	14	TATGGCAAAAGAAATCAAAATTTTACAGACATGGCGTGTCCCATGGTGGCGGAGATTGA	73
Db	484	TATGTCAAAAGAAATTAATTTTCTCAGATGCCGCTTCACTATGGTCCGTGGATGCA	54
QY	74	TATGTGGCGATACCGTCAAAAGTAAGCGTGGTCCCTAAAGGGCGCAATGTGTCTTGA	133
Db	544	TATCCTTGCAGATACCTGTTAAAGTAACCTTGGAGACCAAAAGATGCGCAATGCTCTCTTGA	607
QY	134	AAAAGCTTTGGTCTTCTCCCTTAATTAATTAATGACGGGGTAACCATTCCTTAAGAGATGA	193
Db	604	AAATATCATTTGGCTCACCATTAATTAACCAATGACGGTGTGACTTTGCCAAAAGAAATTGA	663
QY	134	ATTGAAAGATCATTTTGAAGAAACATGGAGCAAAATTTGGTGTGTAAGTGGCTCTTAAAC	253
Db	664	ATTGAAAGACCATTTTGAAGAAATATGGGTGGCAAAATTTGGTATATACAACTACTCTTAAAC	723
QY	254	CAATGATATTGCTGTGATGAGGAGCACTACTGCAACAGTTTGGACACAGCCATTGTTC	313
Db	724	CAATGATATTGCGACGGGACGGGAATACAGATCGAACACTTCTGGACCAAGCATATGTCCG	783
QY	314	TGAAGGACTAAAAATGTGACAGCAGCGTGTATCAATTTGTTATCGTCGACGAGCATGA	373
Db	784	TGAAGGAAATAAAAACGTCACAGCGAGGTGCAATTCATTCGATATTCGTCGAGGATGA	843
QY	374	AACAGCAACAGCAACAGCTGTGAAGCGCTTGAAGCCATTTGCTCAACCTGTATCTGGCA	433
Db	844	AACAGCAAGTTGGCGGACAGCATTTGAAGCTTTTGTGAAGAAACAAGCCATCCCTGTGGCAATAA	903

PT pneumonae
XX
PS Claim 1: Page 628-631: 1409pp: English.

CC The present invention describes a computer readable medium which has
CC the nucleotide sequences SEQ ID NO:1 to 391 (AAV52134 to AAV52524)
CC recorded on it, or a representative fragment or a sequence at least 95%
CC identical to SEQ ID NO: 1 to 391. The nucleotide sequences depicted in
CC SEQ ID NO:1 to 391 (AAV52134 to AAV52524) are genomic fragments from
CC *Streptococcus pneumoniae*. The present invention also describes an
CC isolated nucleic acid molecule encoding a homologue of any of the
CC fragments of the *S. pneumoniae* genome (SEQ ID NO:1 to 391) where the
CC nucleic acid molecule is produced by a process comprising: (a) screening
CC a genomic DNA library using as a probe a target sequence defined by any
CC of the sequences in SEQ ID NO:1 to 391, identifying members of the
CC library which contain sequences that hybridize to the target sequence and
CC isolating the nucleic acid molecules from the members; or (b) isolating
CC mRNA, DNA or cDNA produced from an organism, amplifying nucleic acid
CC molecules whose nucleotide sequence is homologous to amplification
CC primers derived from the fragment of the *S. pneumoniae* genome to prime
CC the amplification and isolating the amplified sequences. The computer
CC readable medium can be used in a computer-based system for identifying
CC fragments of the *S. pneumoniae* genome of commercial importance, or
CC expression modulating fragments of the *S. pneumoniae* genome. Products
CC from the present invention can be used in diagnosis kits and assays, and
CC pharmaceutical compositions and vaccines for *S. pneumoniae*.

Sequence 5365 BP; 1654 A; 960 C; 1082 G; 1669 T; 0 other:

Query Match 62.3% Score 1035.4; DB 19; Length 5365;
Best Local Similarity 77.4%; Pred. No. 4,66-361;
Matches 1255; Conservative 0; Mismatches 366; Indels 0; Gaps 0;

14 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 73
DB 277 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 336
OY 74 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 133
DB 337 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 396
OY 134 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 193
DB 397 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 456
OY 194 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 253
DB 457 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 516
OY 254 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 313
DB 517 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 576
OY 314 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 373
DB 577 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 636
OY 374 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 433
DB 637 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 696
OY 434 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 493
DB 697 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 756
OY 494 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 553
DB 757 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 816
OY 554 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 613
DB 817 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 876

OY 614 ATACATGTCACAGACAAATGAAAAATGCTGACAGACTTGAACCAATTTACTTAAT 673
DB 877 GTACATGTCACAGACAAATGAAAAATGCTGACAGACTTGAACCAATTTACTTAAT 936
OY 674 CACGATTAATAAGTGCACAAATCCAAAGACATTTTCCACTACTTGAAGAACTTTTAA 733
DB 937 TACGACAAAGAAATTTTCAATTCACAAAGAAATTTTCCACTACTTGAAGAACTTTTAA 996
OY 734 AACCAACGCTTCATTAATTAATGACATGATGATGATGATGATGATGATGATGATGATGAT 793
DB 997 AACCAACGCTTCATTAATTAATGACATGATGATGATGATGATGATGATGATGATGATGAT 1056
OY 794 TGTCTGAAACAAAGATTCGTGATGATGATGATGATGATGATGATGATGATGATGATGAT 853
DB 1057 TGTCTGAAACAAAGATTCGTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1116
OY 854 TGATCTGCTTAACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 913
DB 1117 TGACCTGCTTAACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1176
OY 914 AGAGATCTAGGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 973
DB 1177 AGAGATCTAGGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1236
OY 974 GATTACAGTGAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1033
DB 1237 AGTACAGTGAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1296
OY 1034 TGTCAACGCTTCATTAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1093
DB 1297 TGTCAACGCTTCATTAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1356
OY 1094 TGAACAACTGACAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1153
DB 1357 TGAACAACTGACAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1416
OY 1154 AGCTCCACAGACAGACCTTTAAAGAAATGATGATGATGATGATGATGATGATGATGATGAT 1213
DB 1417 AGCTCCACAGACAGACCTTTAAAGAAATGATGATGATGATGATGATGATGATGATGATGAT 1476
OY 1214 TACACGTCAGCCTTGAAGAAAGATGATGATGATGATGATGATGATGATGATGATGATGAT 1273
DB 1477 TACACGTCAGCCTTGAAGAAAGATGATGATGATGATGATGATGATGATGATGATGATGAT 1336
OY 1274 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 1333
DB 1537 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 1396
OY 1334 GCTTCGTCGCTTAAGAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1393
DB 1537 TCTCGTCGTCGCTTAAGAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1456
OY 1394 GCTTCGTCGCTTAAGAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1453
DB 1657 TATGCAAAAGAAATCAATTTTCAGACATGCGGTGCTGCGCATGTCGCGAGATTGA 1716
OY 1454 TGAGTGGTGAATGATTAATAACAGAAATCATGATGATGATGATGATGATGATGATGATGATGAT 1513
DB 1717 TGAGTGGTGAATGATTAATAACAGAAATCATGATGATGATGATGATGATGATGATGATGATGAT 1776
OY 1514 GCTTCGTCGCTTAAGAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1573
DB 1777 CTTCAAAATGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1636
OY 1574 TAAACCTGAACCACTTACAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 1633
DB 1837 TAAACCTGAACCACTTACAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 1896
OY 1634 G 1634
DB 1897 G 1897

RESULT 14
AAH56859
ID AAH56859 standard; DNA; 2401 BP.
XX
AC AAH56859;
XX
DT 06-SEP-2001 (first entry)
XX
DE S. pneumoniae groE operon nucleotide sequence SEQ ID NO:5.
XX
KM Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KM microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KM Streptococcus pyogenes; Streptococcus aureus; pseudomonas aeruginosa;
KM antibacterial; antiviral; antiproliferative; antisense therapy;
KM microbial infection; ds.
XX
OS Streptococcus pneumoniae.
XX
PN MO200136625-A2.
XX
PD 25-MAY-2001.
XX
PF 20-NOV-2000; 2000MO-CA01347.
XX
PR 18-NOV-1999; 99US-0166249.
XX
PA (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI Wright JA, Young AH, Dugourd D;
XX
DR WPI: 2001-355633/37.
XX
PT Novel antisense compounds targeting nucleic acid encoding groE or
PT groES gene of microorganism, which hybridize with and inhibit
PT expression of the genes, useful to inhibit growth of microorganism
PT having the genes -
XX
XX
PS Disclosure: Fig 5; 110pp; English.
XX
XX The present invention specifically claims AAH56368 to AAH56832 which are
CC antisense oligonucleotides to nucleotide sequences encoding groE. More
CC generally, antisense compounds (I) comprising antisense oligonucleotides
CC of 5-50 bases targeted to a nucleotide sequence encoding groE (heat
CC shock protein (Hsp)60) (G1), and groES (Hsp10) (G5) gene from a
CC microorganism, where the antisense compound is complementary to G1 or
CC G5 or a microorganism and specifically hybridizes with and inhibits the
CC expression of G1 or G5, is claimed. (I) have antibacterial, antiviral
CC and antiproliferative activities, and can be used in antisense therapy
CC and for inhibition of expression of groE or groEL. (I) are useful for
CC inhibiting expression of groE or groEL in cells or tissues in vitro. (I) are
CC also useful for inhibiting the growth of a microorganism, or inhibiting
CC the expression of G1 or G5 gene in a microorganism (a bacterial cell or
CC a virus) having a G1 or G5 gene which involves administering to the
CC microorganism or to a cell infected with the microorganism, (II). (I) are
CC also useful for treating a mammalian pathological condition mediated by
CC the microorganisms which involves identifying a eukaryotic organism G1
CC or G5 gene and administering (I) such that the growth of microorganism
CC is inhibited. The antisense compounds are utilized for diagnostics,
CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC prevent or delay microbial infections in humans. They are also useful as
CC molecular weight markers. AAH56367 to AAH56367 and AAH56832 to AAH56834
CC represent PCR primers for groE sequences which are used in the
CC amplification of the present invention. AAH56835 to AAH56870 represent
CC groE nucleotide sequence given in the present invention.
XX
XX Sequence 2401 BP; 743 A; 459 C; 568 G; 631 T; 0 other;

Query Match 62.0%; Score 1030.6; DB 22; Length 2401;
Best Local Similarity 77.2%; Pred. No. 6,1e-260;
Matches 1252; Conservative 0; Mismatches 369; Indels 0; Gaps 0;

DB 618 TATGTCAAGAAATTAATTTTCATGACAGATGCGCTGACGATGCTGTGTGCA 677
QY 74 TATGTACGATACCGTCAAAAGTAAACCTTGTCTTAAAGGCGCAATGTTCTTGA 133
DB 678 TATCTTCGACAGACTGTAAAGTAACTGAGTGGACCAAAAGATGCAATGTGTTCTGA 737
QY 134 AAAAGCTTTGCTTCCTTAATTAATTAAGTGAAGGGAACCTGCTTAAGACATGA 193
DB 738 AAAGTCTTCGCTTACCTTGAATTAACCAATGAGCGGTGACATTCGCAAGAAATGCA 797
QY 194 ATTAGAAGATCAATTTTGAAGACATGAGCAAAATGCTGTCTGAAGTCTTGAAC 233
DB 798 ATTGGAAGACATTTTGAAGATGAGGTGCTAAGTATGATCAAGAAATGCTTGAAC 857
QY 254 CAATGATATGCTGTGATGAGACAGACTGACACAGTTTGAACAGCCATTGTCA 313
DB 858 CAATGATATGCTGTGATGAGACAGACTGACACAGTTTGAACAGCCATTGTGCG 917
QY 314 TGAAGACTAATAAATGTGACAGAGGTGTAATCCAAATGATGATGCGAGCATGGA 373
DB 918 TGAAGGAATCAAAACCTGACAGAGGTGCAAAATCCAAATGATGATGCGAGCATGGA 977
QY 374 AACAGCAACAGCAAGCTGTTGAAGCTTGAAGCAATGCTCAACACTGATATGCGCAA 433
DB 978 AACAGCAAGTGGCCGACAGGTGAAAGCTTTGAAACCAAGCCATCCCTGTGCAATTA 1037
QY 434 GGAAGCTATGCTGAGTGGCTGACATATGATGATGATGATGATGATGATGATGAT 493
DB 1038 AGAAGCTATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1097
QY 494 CTCAGAGCTATGAGAGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 553
DB 1098 CTCAGAGCTATGAGAGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1157
QY 554 TATGGAACAGAACTGAAAGTGTGGAAGGATGCAATTTGACGCTGTACTGTCTCA 613
DB 1158 TATGGAACAGAACTGAAAGTGTGGAAGGATGCAATTTGACGCTGTACTGTCTCA 1217
QY 614 ATACATGCTGACAGCAATGAAATGATGATGATGATGATGATGATGATGATGATGAT 673
DB 1218 GTACATGCTGACAGCAATGAAATGATGATGATGATGATGATGATGATGATGATGAT 1277
QY 674 CACGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 733
DB 1278 TACAGCAAGAAATTTCAATATCCAAATGCAAGAAATTTGCAATTTGCAATTTGCA 1337
QY 734 AACCAAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 793
DB 1338 AACCAAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1397
QY 794 TGTCTGAAACAATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 853
DB 1398 TGTCTGAAACAATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1457
QY 854 TGTCTGAAACAATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 913
DB 1458 TGTCTGAAACAATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1517
QY 914 AGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 973
DB 1518 AGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1577
QY 974 GATTAAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1033
DB 1578 AGTACGCTGACAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1637
QY 1034 TGTCTGAAACAATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1093
DB 1638 TGTCTGAAACAATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1697
QY 1094 TGAAGAACTCAAGAACTTTGAGGAAATTAAGTGTGATGATGATGATGATGATGATGAT 1153

Db 1698 TGAATAATTCAGAACGCTTGCCAAATTTGTCAGTGTGATGCGGTATTAAGTTCG 1757
 Oy 1154 ACCTCAACAGAGACAGCTTTAAAGAAATGCGATTTAGAGATGCTGCTAAATGC 1213
 Db 1758 ACCGCAACTGAACTGAGTTGAAAGAAATGAACTCCGATTTGAAGTCCCTCAAGC 1817
 Oy 1214 TACAGTGCAGCGCTTGAAGAAAGTATGCTGTGAGTGGAGACAGACTTAAACGT 1273
 Db 1818 TACTGTGCAGCTGTTGAAGAAAGTATTTGTCAGTGTGAGACAGCTTCCAAATG 1877
 Oy 1274 TATGAAAAGTACAGCTCTGTGAGTGGAGGAGATGCTACTAGTACGTAACATGT 1333
 Db 1878 GATTTCAGCTGAACTGCTGATTTGACAGAGATGAGACAGAGCTAAATTTGT 1937
 Oy 1334 GCTTCGCTCTTGAAGAGCTGTAGTCAATTTGCTTAAATGCTGGAGACAGCTC 1393
 Db 1938 TCTCGGCTTTGAGAACCCGCTGCTAAATGCTCAACATGCAAGATTTAAAGATC 1997
 Oy 1394 CGTAGTATGACAGTGAAGAAACAGCCCTGACAGAGAGATTTAATCTGCAACAG 1453
 Db 1998 TATGCTATGATCGTTGAAAAATCTGAGCTGTGATAGATTTAAACGCAACATCG 2057
 Oy 1454 TATGAGGTTGATATGATTTAAACAGAGATCATTTGACCTGTCAAGTAACAGATCAG 1513
 Db 2058 CGAGTGGTTAAACATGATTTGATGATGATGATGATGATGATGATGATGATGATG 2117
 Oy 1514 GCTTCAAAATGACGCTTCTGAGTGTGATTTATTTGACAGAGAGATTTGATTTGCTAA 1573
 Db 2118 CCTCAAAATGACGATCTGATGATGATGATGATGATGATGATGATGATGATGATG 2177
 Oy 1574 TAAAGCTGAACAGCTAGCGAGCGCAATCCAGAGTATGATGATGATGATGATGATG 1633
 Db 2178 TAAACGAAACGATGAGCCCACTGACAGATGATGATGATGATGATGATGATGATG 2237
 Oy 1634 G 1634
 Db 2238 G 2238

 RESULT 15
 ID ABA90521 standard: DNA: 2365589 BP.
 AC ABA90521:
 XX 16-MAY-2002 (first entry)
 DE Genomic sequence of *Lactococcus lactis* IL1403.
 KM Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese; ds.
 OS *Lactococcus lactis* IL1403.
 PN FR2807446-A1.
 PD 12-OCT-2001.
 PF 11-APR-2000: 2000FR-0004630.
 PR 11-APR-2000: 2000FR-0004630.
 PA (INRG) INRA INST NAT RECH AGRONOMIQUE.
 PI Boletine A, Sorokline A, Renault P, Ehrlich SD:
 PT WPI; 2002-04318/06.
 PS New nucleotide sequence useful in the identification of *Lactococcus*
 CC Lactis and related species.
 CC Claim 1: SEQ ID 1: 2504bp; French.
 CC The present invention is related to a *Lactococcus lactis* nucleotide

CC sequence (ABA90521) and related proteins (AB53300-AB55621). The
 CC nucleic acid sequence is useful in the detection and/or amplification of
 CC related species. The proteins of the invention are useful for the
 CC biosynthesis or biodegradation of a composition of interest. The
 CC invention helps research in lactic bacteria, particularly useful in the
 CC production of yogurt and cheese.
 CC Note: The sequence data for this patent is based on equivalent patent
 CC WO200177334 (published 18-Oct-2001) which is available in electronic
 CC format directly from WIPO at http://wipo.int/pub/published_pat_sequences.
 XX
 SO Sequence 2365589 BP; 765914 A; 415261 C; 420487 G; 763927 T; 0 other;

 Query Match 57.58; Score 955; DB 24; Length 2365589;
 Best Local Similarity 75.18; Pred. No. 6,4e-239;
 Matches 1192; Conservative 0; Mismatches 395; Indels 0; Gaps 0;

 Oy 11 TCATATGCAAAAGAAATCAATTTTACAGATGCGGTGCTGCCATGCGCGAGT 70
 Db 398893 TAAATGCAAAAGAAATCAATTTTACAGATGCTGACAGAGATGCGTGGAT 398952
 Oy 71 TGATATGTTAGCATACCGTCAAGTAACGCTGTCTAAAGGCCCAATGTGTTCT 130
 Db 398953 TGATATGTTGCTGATACAGTAACACCTTGACCAAAAGTCCAAATGTTGTT 399012
 Oy 131 TGAAGACCTTTGTTCTCCCTTAATTAATGACGCGGTAAACCATTTGCTAAAGAT 190
 Db 399013 TGAAGACCTTTGTTCTCCCTTAATTAATGACGCGGTAAACCATTTGCTAAAGAT 399072
 Oy 191 GCAATTAAGATCATTTTGAAGAACATGAGGACAAATTTGTGTGAGAGGCTTCTAA 250
 Db 399073 TGAATGGAAGATCATTTTGAAGAACATGAGGACAAATTTGTGTGAGAGGCTTCTAA 399132
 Oy 251 AACCAATGATATTTGTTGATGAGGACGATCTGCAACAGTTTGAACACAGCATTTGT 310
 Db 399133 AACCAATGATATTTGTTGATGAGGACGATCTGCAACAGTTTGAACACAGCATTTGT 399192
 Oy 311 TCATGAGGACCTAAAGAAATGACAGAGCTGATCAATTTGATTCGCTGAGAGCAT 370
 Db 399193 TCATGAGGACCTAAAGAAATGACAGAGCTGATCAATTTGATTCGCTGAGAGCAT 399252
 Oy 371 TGAAGACGTAACAGAGCTGTGAAGCCATTTGCAACGCTGATCTGATCTGAG 430
 Db 399253 TGAAGACGTAACAGAGCTGTGAAGCCATTTGCAACGCTGATCTGATCTGAG 399312
 Oy 431 CAAGAGCATTTGCTGAGTGCCTGATCATCATCATCATCATCATCATCATCATCATCAT 490
 Db 399313 TAAATCATCATTTGCTGAGTGCCTGATCATCATCATCATCATCATCATCATCATCAT 399372
 Oy 491 TATCTCAAGCTATGAGAGCGTGGCAACGATGTGTGATTAACATCGAAGATCTCG 550
 Db 399373 TATCTCTGATGCAATGAGAGCGTGGTGTGCAAGGATTAACATCGAAGATCTCG 399432
 Oy 551 AGCATATGAAAGAGACTTGAAGTGTGAAGCATGCAATTTGACCGTGTACTGTC 610
 Db 399433 AGCATATGAAAGAGACTTGAAGTGTGAAGCATGCAATTTGACCGTGTACTGTC 399492
 Oy 611 TCAATACATGCTACAGCAATGAAAAATGTTGCGAGCCTTGAAGAACCATTTACTCT 670
 Db 399493 TCAATACATGCTTCTAATACAGAAAAATGTTGCGAGTATGATTAATCTTATTTCT 399552
 Oy 671 AATACGAGAAAAAGTGCACATCCAGACATTTTGCATCTGATGAGAGTCT 730
 Db 399553 TATTAACGAGAAAAAGTGCACATCCAGACATTTTGCATCTGATGAGAGTCT 399612
 Oy 731 TAAACCAACGCTCATTAATCTATTTGACAGATGATGAGTGAAGCATCTTCAAC 790
 Db 399613 GAAACCAACGCTCATTAATCTATTTGACAGATGATGAGTGAAGCATCTTCAAC 399672
 Oy 791 CTTGTCTTGAACAGATGCTGTACTTCAATGTGTGCTGTGCAAGCGCAGAGAT 850
 Db 399673 CTTGTCTTGAATGAAGTGAAGTGTCTCAATGTGTGCTGTGCAAGCGCAGAGAT 399732

Wed Apr 16 08:05:36 2003

us-09-001-737-7.rng

Page 19

OY	851	TGCTGTCGTCGTAAGCTATCGTTCAGACATGCTATCTTTCACAGCTGCTACAGTAT	910
Db	39973	TGCTGTCGTCGTAAGCTATCGTTCAGACATGCTATCTTTCACAGCTGCTACAGTAT	399792
OY	911	TACAGAGATCTAGCACTGTAATTTAAAGATGCTACATGACACCCCTTGACAGGCTGC	970
Db	399793	TACAGAGATCTAGCACTGCTGATCTTTAAAGATGCTACTCTTGACACTTTAGCAAGAGAC	399852
OY	971	TGAGATTACGTTGATTAAGATAGCACAGTAAATGTTGAGAGTTCAGAGATTCAGAAC	1030
Db	399853	TGAGCAACCTGTGTGATTAAGACACACACAACTTGTGAGAGTGTGCTGTGTGTATGC	399912
OY	1031	TATTCCTAACCGTATATGCTACTGATTTAAATCCAAATTAGAAACAACATCTGCCTTGA	1090
Db	399913	TATTCCTGATCGTAGCTATATTTAAAGCCCAAAATGTGAAAAACAATCTGATTTGA	399971
OY	1091	CCGTGAAAAAATCAAGAGAGTGTGGCAAAATAGCTGTGTGTAGCTGTATCAAAAT	1150
Db	399973	TGCTGAAAAAATTCAGAGAGCTTGCACAAATTAGCTGTGTGTGTGTGTGTGTAAAT	400032
OY	1151	AGACAGCTCCAAAGAGAGACCTTTAAAGAAATGAAGAACTGTGATGAGATGCTTAA	1210
Db	400033	TGCTGTCTGCACAGAAACAGAGCTCAAGCAATGAAATCTGTGATGAGATGAGACTTAA	400092
OY	1211	TGCTACAGCTGCGACCGCTGTAGAAAGATTCGTGTGTGTGTGTGTGTGTGTATAC	1270
Db	400093	TGCACACCTGACGCCCTGTAGAAAGATTTGTTGTGTGTGTGTGTGTGTGTGTAA	400152
OY	1271	GCTTTTGAAAAAGTACAGCTCTTGAGCTTGAAGGCGATGATGCTACTGACGTAAAT	1330
Db	400153	TGCTATTTGCTGCTTGGATTAACCTTTCAGAAAGAAAGATTTCAACAGGTATTTAAAT	400212
OY	1331	TCTGCTGCTGCTGTAGAGAGCTGTACGTCAAAATTCCTTTAAATGCTGTGTACAAAG	1390
Db	400213	TCTTGCGCGCTGCTGTAGAAACAGATTCGTCAAAATTCGTCCAAATGCAAGATATAGAG	400272
OY	1391	CTCGGTGATTATTCACAATGTGAANAACCCCTGCAGGAACAGATTTAATCTCTCAAC	1450
Db	400273	TTCAATATATCATTTGATAAATTCGTTCAGAAAGAAATGATGTCAGGATTCATCTCTCAAC	400332
OY	1451	AGCTGATGTGCTGATATGATTTAAACAGGAATCTTACCTGTCAAGTAACAGAGAT	1510
Db	400333	TGCTCATATGCTTAATATGATTAAGAAAGAAATGTGTACCTGCAAAAGTATCTCTTC	400392
OY	1511	ACCGCTCAAAATGACCTCTGTGTAGCTATCTTTATGACAAAGAGAGATGTTCG	1570
Db	400393	ACCTTTCAAAACGGGCTCTGTGTGTGTATTTTGTACTAGAAAGATGATTTGC	400452
OY	1571	TATTAACCTGACAGACTTACCCAGC	1597
Db	400453	TATTAACCTGACAGACTTACCTCAGC	400479

Search completed: April 15, 2003, 01:18:55
Job time : 3259.59 secs